BioXcel Therapeutics is trading 5.42% up now at $0.83 after an amended credit agreement extended the deadline for securing lender-approved financing or repaying obligations to August 21, 2026.
- The amendment lowered the minimum cash-liquidity covenant to $3.0 million from $6.25 million.
- The change provides temporary liquidity relief while highlighting continuing financing pressure.
- The broader market is only modestly higher, making the company-specific financing update the apparent primary catalyst.